Biolex is developing a revolutionary system for the recombinant production of therapeutic proteins. The company’s business model has two major components: 1) development of proprietary “Biolex Proteins” and 2) co-development projects with other biopharma companies. The lead Biolex Protein is in Phase 2 trials for
Hepatitis C.

King of Prussia, PA

Uses a proprietary protein engineering platform and a modified form of transferrin to enhance half life, efficacy, and safety of proteins; initially targeting diabetes

Acquired by Pfizer in February 2007

Princeton, NJ

Identifies ratios of synergistic drug combinations in vitro, and fixes ratios in liposomal drug carriers for in vivo treatment of various cancers

Philadelphia, PA

Uses a platform, CB-CAPs (Cell-Bound Complement Activation Products), to develop an early identification and monitoring solution for autoimmune diseases

Developing therapeutics and diagnostics based on Complement Factor H (CFH) research to treat for the dry form of age related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN-II)

Provider of innovative single molecule and single cell analysis solutions that enable discovery of common and rare regions of genomic interest. Proprietary microdroplet technology has broad applications in genomic research, development of clinical diagnostics, compound screening, and biomarker detection